Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Innovent starts dosing cancer patients in Phase I trial of IBI188

IBI188 is a fully human monoclonal antibody designed to target the CD47 antigen on tumour cells. Credit: Penn State/Flickr.



  • IBI188 dosing begins in Phase I trial

Go Top